826 related articles for article (PubMed ID: 22587791)
1. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
Feldman SR; Mills M; Brundage T; Eastman WJ
J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
4. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
6. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
7. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
8. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
9. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
10. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
Bhatia N; Stein Gold L; Kircik LH; Schreiber R
J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
[TBL] [Abstract][Full Text] [Related]
11. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
[TBL] [Abstract][Full Text] [Related]
12. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
[TBL] [Abstract][Full Text] [Related]
13. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield LF; Ganslandt C; Kurvits M; Schlessinger J
Pediatr Dermatol; 2015; 32(1):28-35. PubMed ID: 25412565
[TBL] [Abstract][Full Text] [Related]
16. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL
Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
[TBL] [Abstract][Full Text] [Related]
19. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
White S; Vender R; Thaçi D; Haverkamp C; Naeyaert JM; Foster R; Martinez Escribano JA; Cambazard F; Bibby A
Am J Clin Dermatol; 2006; 7(3):177-84. PubMed ID: 16734505
[TBL] [Abstract][Full Text] [Related]
20. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.
Koo J; Blum RR; Lebwohl M
J Am Acad Dermatol; 2006 Oct; 55(4):637-41. PubMed ID: 17010744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
